{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:31:39Z","timestamp":1790217099034,"version":"4.1.0"},"reference-count":132,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Improvement and maintenance of bulbar function are important goals of disease-modifying treatments (DMTs) for spinal muscular atrophy (SMA), but standardized and validated measures for assessing bulbar function do not exist, nor does a widely accepted definition of bulbar function in SMA. As such, the impact of DMTs on bulbar function has not yet been comprehensively evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>We conducted a systematic literature review (SLR) to identify evidence about the impact of DMTs for SMA on bulbar function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We used the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines to conduct this review. Embase\n                      <jats:sup>\u00ae<\/jats:sup>\n                      and MEDLINE\n                      <jats:sup>\u00ae<\/jats:sup>\n                      databases were searched through August 10, 2023. Eligible studies included patients with SMA who were treated with any DMT and reported bulbar function outcomes. Non-English studies were excluded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We identified 51 studies (across 83 publications) that evaluated SMA DMTs and bulbar function for more than 1600 patients. The ability to feed orally, the ability to tolerate liquids, and the need for nutrition support were commonly reported. Most infants treated with any DMT before SMA symptom onset preserved bulbar function. Infants, children, and adults treated after SMA symptom onset experienced variable results in terms of bulbar function outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The definition and assessment of bulbar function are not standardized. Therefore, the tools, scales, methods, and timing used for bulbar function assessments varied among studies. Larger prospective studies using standardized and age-based assessments with longer follow-up periods are needed to assess the clinical stability of bulbar function for patients with SMA who receive DMTs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/22143602241303373","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T08:58:56Z","timestamp":1734685136000},"page":"195-217","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Systematic literature review of the impact of spinal muscular atrophy therapies on bulbar function"],"prefix":"10.1177","volume":"12","author":[{"given":"Katlyn","family":"McGrattan","sequence":"first","affiliation":[{"name":"Department of Speech-Language-Hearing Sciences, University of Minnesota, Minneapolis, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Walsh","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Lurie Children's Hospital, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5460-4493","authenticated-orcid":false,"given":"Lesa","family":"Mehl","sequence":"additional","affiliation":[{"name":"Biomedical Research, Novartis, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simarjeet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Novartis, Madhapur \/ Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith W","family":"Dilly","sequence":"additional","affiliation":[{"name":"Novartis Gene Therapies, Inc., Bannockburn, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2670"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2015.07.004"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-26.5.437"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.01.003"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2007.02.006"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7154-1"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2016.00007"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S172291"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.09.007"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.004"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0724-z"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.005"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-221531"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11091244"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-020-10126-x"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190436"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNP.0000000000000186"},{"key":"e_1_3_6_19_2","doi-asserted-by":"crossref","unstructured":"Dunaway Young S Pasternak A Duong T et al. Assessing bulbar function in spinal muscular atrophy using patient-reported outcomes. 2023; 10: 199\u2013209. doi: https:\/\/doi.org\/10.3233\/JND-221573","DOI":"10.3233\/JND-221573"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/joor.13220"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedneo.2022.01.002"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17238989"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu13072400"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-71"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006241"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9091(98)80026-0"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-021-10351-y"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073807305788"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedneo.2022.09.016"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1366943"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1704732"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27853"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00001-6"},{"key":"e_1_3_6_34_2","unstructured":"Finkel RS Kuntz N Mercuri E et al. Primary efficacy and safety results from the Phase 3 ENDEAR study of nusinersen in infants diagnosed with spinal muscular atrophy. Presented at: British Paediatric Neurology Association Annual Conference; January 11\u201313 2017; Cambridge UK."},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.07.183"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00339-8"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00251-9"},{"key":"e_1_3_6_40_2","unstructured":"Servais L Farrar MA Vlodavets D et al. RAINBOWFISH: preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA). Oral presentation presented at: SMA Europe 2022; October 21\u201322 2022; Barcelona Spain."},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01866-4"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01867-3"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-221672"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2023.06.005"},{"key":"e_1_3_6_45_2","article-title":"Preserved swallowing function in infants who initiated nusinersen treatment with presymptomatic SMA: NURTURE study results","volume":"8","author":"Sansone V","year":"2021","unstructured":"Sansone V, Swoboda K, De Vivo D, et al. Preserved swallowing function in infants who initiated nusinersen treatment with presymptomatic SMA: NURTURE study results. J Neuromuscul Dis 2021; 8: S130.","journal-title":"J Neuromuscul Dis"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.07.307"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.92.15_supplement.S25.001"},{"key":"e_1_3_6_48_2","first-page":"227","article-title":"Swallowing function in children with later-onset spinal muscular atrophy treated with nusinersen: CHERISH-SHINE results","volume":"29","author":"Muntoni F","year":"2022","unstructured":"Muntoni F, Crawford T, Castro D, et al. Swallowing function in children with later-onset spinal muscular atrophy treated with nusinersen: CHERISH-SHINE results. Eur J Neurol 2022; 29: 227.","journal-title":"Eur J Neurol"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(21)00100-0"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190465"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac252"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.02.001"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.25795"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27425"},{"key":"e_1_3_6_55_2","first-page":"80","article-title":"Oro-bulbar involvement in paediatric patients with SMA type 2 and 3","volume":"41","author":"Trucco F","year":"2022","unstructured":"Trucco F, Salmin F, Lizio A, et al. Oro-bulbar involvement in paediatric patients with SMA type 2 and 3. Acta Myol 2022; 41: 80.","journal-title":"Acta Myol"},{"key":"e_1_3_6_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-023-10584-z"},{"key":"e_1_3_6_57_2","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2022-323899"},{"key":"e_1_3_6_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51276"},{"key":"e_1_3_6_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15768"},{"key":"e_1_3_6_60_2","doi-asserted-by":"publisher","DOI":"10.5603\/PJNNS.a2021.0020"},{"key":"e_1_3_6_61_2","first-page":"694","article-title":"The efficacy of intrathecal nusinersen on the ability to wean from mechanical ventilation in patients with SMA type 1","volume":"70","author":"Eddington K","year":"2022","unstructured":"Eddington K, Katz R. The efficacy of intrathecal nusinersen on the ability to wean from mechanical ventilation in patients with SMA type 1. J Investig Med 2022; 70: 694\u2013695.","journal-title":"J Investig Med"},{"key":"e_1_3_6_62_2","article-title":"SMA \u2013 treatment: EP.276 Bulbar function evolution in SMA type 1 children treated with nusinersen","volume":"31","author":"Weststrate H","year":"2021","unstructured":"Weststrate H, Stimpson G, Thomas L, et al. SMA \u2013 treatment: EP.276 Bulbar function evolution in SMA type 1 children treated with nusinersen. Neuromuscul Disord 2021; 31: S133\u2013S134.","journal-title":"Neuromuscul Disord"},{"key":"e_1_3_6_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.15171"},{"key":"e_1_3_6_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2020.09.002"},{"key":"e_1_3_6_65_2","article-title":"SMA \u2013 Clinical: P.85. Evolution at 18 months of SMA type 1 patients treated with nusinersen","volume":"30","author":"De Lucia S","year":"2020","unstructured":"De Lucia S, Phelep A, Seferian A, et al. SMA \u2013 Clinical: P.85. Evolution at 18 months of SMA type 1 patients treated with nusinersen. Neuromuscul Disord 2020; 30: S72.","journal-title":"Neuromuscul Disord"},{"key":"e_1_3_6_66_2","article-title":"Outcomes in spinal muscular atrophy infants on nusinersen therapy","volume":"60","author":"Kaltman J","year":"2019","unstructured":"Kaltman J, Verma S. Outcomes in spinal muscular atrophy infants on nusinersen therapy. Muscle Nerve 2019; 60: S7.","journal-title":"Muscle Nerve"},{"key":"e_1_3_6_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.06.531"},{"key":"e_1_3_6_68_2","first-page":"53","article-title":"Nutritional status in SMA type 1 over a 6 month follow-up in Nusinersen Expanded Access Program (EAP)","volume":"37","author":"Messina S","year":"2018","unstructured":"Messina S, Sframeli M, Bruno C, et al. Nutritional status in SMA type 1 over a 6 month follow-up in Nusinersen Expanded Access Program (EAP). Acta Myol 2018; 37: 53\u201354.","journal-title":"Acta Myol"},{"key":"e_1_3_6_69_2","first-page":"65","article-title":"Oro-facial and bulbar involvement in SMA (OBI-SMA): outcome measures & endpoint assessments","volume":"40","author":"Salmin F","year":"2021","unstructured":"Salmin F, Cattaneo C, Lops J, et al. Oro-facial and bulbar involvement in SMA (OBI-SMA): outcome measures & endpoint assessments. Acta Myol 2021; 40: 65.","journal-title":"Acta Myol"},{"key":"e_1_3_6_70_2","first-page":"26","article-title":"Would you invest in a SMA patient with only 1 copy of SMN2? What if you knew they could walk?","volume":"63","author":"Bryan C","year":"2021","unstructured":"Bryan C, Marco DI, Mochrie R, et al. Would you invest in a SMA patient with only 1 copy of SMN2? What if you knew they could walk? Dev Med Child Neurol 2021; 63: 26\u201327.","journal-title":"Dev Med Child Neurol"},{"key":"e_1_3_6_71_2","article-title":"Dysphagia in two children with spinal muscular atrophy (SMA) type 1 treated with nusinersen","volume":"12","author":"Deshpande S","year":"2020","unstructured":"Deshpande S, Gormley C. Dysphagia in two children with spinal muscular atrophy (SMA) type 1 treated with nusinersen. PM R 2020; 12: S160.","journal-title":"PM R"},{"key":"e_1_3_6_72_2","first-page":"83","article-title":"Maximum bite force in patients with spinal muscular atrophy during the first year of nusinersen therapy \u2013 A pilot study","volume":"39","author":"Kruse T","year":"2020","unstructured":"Kruse T, Heller R, Wirth B, et al. Maximum bite force in patients with spinal muscular atrophy during the first year of nusinersen therapy \u2013 A pilot study. Acta Myol 2020; 39: 83\u201389.","journal-title":"Acta Myol"},{"key":"e_1_3_6_73_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.2384"},{"key":"e_1_3_6_74_2","doi-asserted-by":"crossref","unstructured":"Strauss K Muntoni F Farrar MA et al. Onasemnogene abeparvovec gene therapy in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update in children with 3 copies of SMN2. Presented at: Muscular Dystrophy Association (MDA) Clinical & Scientific Conference; March 15\u201318 2021; virtual.","DOI":"10.1212\/WNL.96.15_supplement.4163"},{"key":"e_1_3_6_75_2","doi-asserted-by":"crossref","unstructured":"Strauss K Muntoni F Farrar MA et al. Onasemnogene abeparvovec gene therapy in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update in children with 2 copies of SMN2. Presented at: Muscular Dystrophy Association (MDA) Clinical & Scientific Conference; March 15\u201318 2021; virtual.","DOI":"10.1212\/WNL.96.15_supplement.4190"},{"key":"e_1_3_6_76_2","first-page":"9","article-title":"Onasemnogene abeparvovec for presymptomatic infants with spinal muscular atrophy and two copies of SMN2: a phase III study","volume":"64","author":"Muntoni F","year":"2022","unstructured":"Muntoni F, Strauss KA, Farrar MA, et al. Onasemnogene abeparvovec for presymptomatic infants with spinal muscular atrophy and two copies of SMN2: a phase III study. Dev Med Child Neurol 2022; 64: 9.","journal-title":"Dev Med Child Neurol"},{"key":"e_1_3_6_77_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.1484"},{"key":"e_1_3_6_78_2","first-page":"165","article-title":"Onasemnogene abeparvovec-xioi gene therapy in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update","volume":"27","author":"Strauss KA","year":"2020","unstructured":"Strauss KA, Farrar MA, Swoboda KJ, et al. Onasemnogene abeparvovec-xioi gene therapy in presymptomatic spinal muscular atrophy (SMA): SPR1NT study update. Eur J Neurol 2020; 27: 165\u2013166.","journal-title":"Eur J Neurol"},{"key":"e_1_3_6_79_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000202522"},{"key":"e_1_3_6_80_2","doi-asserted-by":"crossref","unstructured":"Finkel RS Benguerba K Gerhani M et al. Outcomes for patients with spinal muscular atrophy (SMA) and four or more SMN2 copies treated with onasemnogene abeparvovec: findings from RESTORE. Presented at: British Paediatric Neurology Association Annual Conference; January 25\u201327 2023; Edinburgh UK.","DOI":"10.1016\/j.nmd.2023.07.270"},{"key":"e_1_3_6_81_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24203"},{"key":"e_1_3_6_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.06.520"},{"key":"e_1_3_6_83_2","article-title":"AVXS-101 phase 1 gene therapy clinical trial in spinal muscular atrophy type 1 (SMA1): improvement in respiratory and bulbar function reduces frequency and duration of hospitalizations compared to natural history","volume":"84","author":"Shell R","year":"2018","unstructured":"Shell R, Al-Zaidy S, Arnold W, et al. AVXS-101 phase 1 gene therapy clinical trial in spinal muscular atrophy type 1 (SMA1): improvement in respiratory and bulbar function reduces frequency and duration of hospitalizations compared to natural history. Ann Neurol 2018; 84: S394.","journal-title":"Ann Neurol"},{"key":"e_1_3_6_84_2","article-title":"AVXS-101 phase 1 gene replacement therapy clinical trial in spinal muscular atrophy type 1: improvement in respiratory and swallowing function stabilizes the need for ventilatory and nutritional support, and reduces frequency and duration of hospitalizations compared with natural history","volume":"67","author":"Shell R","year":"2018","unstructured":"Shell R, Al-Zaidy S, Arnold WD, et al. AVXS-101 phase 1 gene replacement therapy clinical trial in spinal muscular atrophy type 1: improvement in respiratory and swallowing function stabilizes the need for ventilatory and nutritional support, and reduces frequency and duration of hospitalizations compared with natural history. J Pediatr Gastroenterol Nutr 2018; 67: S379.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_3_6_85_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000202549"},{"key":"e_1_3_6_86_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000202555"},{"key":"e_1_3_6_87_2","doi-asserted-by":"crossref","unstructured":"McGrattan KE Shell RD Hurst-Davis R et al. Bulbar function in infants and children with spinal muscular atrophy type 1 following onasemnogene abeparvovec. Presented at: Cure SMA Annual Meeting; June 15\u201317 2022; Anaheim CA.","DOI":"10.1016\/j.nmd.2022.07.182"},{"key":"e_1_3_6_88_2","unstructured":"LaMarca N McGrattan KE Shell RD et al. Bulbar function in patients with spinal muscular atrophy type 1. Presented at: Cure SMA Annual Meeting; June 15\u201317 2022; Anaheim CA."},{"key":"e_1_3_6_89_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00923-8"},{"key":"e_1_3_6_90_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51519"},{"key":"e_1_3_6_91_2","article-title":"Treatment of spinal muscular atrophy with onasemnogene abeparvovec in Switzerland","volume":"9","author":"Stettner G","year":"2022","unstructured":"Stettner G, Hasselmann O, Klein A. Treatment of spinal muscular atrophy with onasemnogene abeparvovec in Switzerland. J Neuromuscul Dis 2022; 9: S194.","journal-title":"J Neuromuscul Dis"},{"key":"e_1_3_6_92_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26285"},{"key":"e_1_3_6_93_2","first-page":"92","article-title":"Review of changes in feeding abilities after treatment with onasemnogene abeparvovec (Zolgensma\u00ae) in children with spinal muscular atrophy type 1: real-world experience at one infusion centre in the United Kingdom","volume":"65","author":"Gowda V","year":"2023","unstructured":"Gowda V, Jungbluth H, Ambegaonkar G, et al. Review of changes in feeding abilities after treatment with onasemnogene abeparvovec (Zolgensma\u00ae) in children with spinal muscular atrophy type 1: real-world experience at one infusion centre in the United Kingdom. Dev Med Child Neurol 2023; 65: 92.","journal-title":"Dev Med Child Neurol"},{"key":"e_1_3_6_94_2","unstructured":"Babu RR Maganthi M Datta D et al. Compassionate treatment for spinal muscular atrophy with viral gene therapy\u2014a single centre experience from India. Presented at: British Paediatric Neurology Association Annual Meeting; January 25\u201327 2023; Edinburgh UK."},{"key":"e_1_3_6_95_2","article-title":"RAINBOWFISH: preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy","volume":"9","author":"Servais L","year":"2022","unstructured":"Servais L, Farrar M, Vlodavets D, et al. RAINBOWFISH: preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy. J Neuromuscul Dis 2022; 9: S114\u2013S115.","journal-title":"J Neuromuscul Dis"},{"key":"e_1_3_6_96_2","first-page":"93","article-title":"RAINBOWFISH: preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA)","volume":"65","author":"Palfreeman L","year":"2023","unstructured":"Palfreeman L, Servais L, Farrar MA, et al. RAINBOWFISH: preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA). Dev Med Child Neurol 2023; 65: 93.","journal-title":"Dev Med Child Neurol"},{"key":"e_1_3_6_97_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2009965"},{"key":"e_1_3_6_98_2","article-title":"FIREFISH Part 1:1-year event-free survival and swallowing ability in infants with type 1 SMA","volume":"51","author":"Seabrook T","year":"2019","unstructured":"Seabrook T, Servais L, Baranello G, et al. FIREFISH Part 1:1-year event-free survival and swallowing ability in infants with type 1 SMA. No To Hattatsu 2019; 51: S225.","journal-title":"No To Hattatsu"},{"key":"e_1_3_6_99_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.92.15_supplement.S25.008"},{"key":"e_1_3_6_100_2","article-title":"FIREFISH Part 1: 24-month safety and exploratory outcomes of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA)","volume":"30","author":"Baranello G","year":"2020","unstructured":"Baranello G, Boespflug-Tanguy O, Darras B, et al. FIREFISH Part 1: 24-month safety and exploratory outcomes of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA). Neuromuscul Disord 2020; 30: S122.","journal-title":"Neuromuscul Disord"},{"key":"e_1_3_6_101_2","first-page":"310","article-title":"FIREFISH Part 1: survival, ventilation and swallowing ability in infants with type 1 spinal muscular atrophy (SMA) treated with risdiplam (RG7916)","volume":"26","author":"Vlodavets D","year":"2019","unstructured":"Vlodavets D, Servais L, Baranello G, et al. FIREFISH Part 1: survival, ventilation and swallowing ability in infants with type 1 spinal muscular atrophy (SMA) treated with risdiplam (RG7916). Eur J Neurol 2019; 26: 310\u2013311.","journal-title":"Eur J Neurol"},{"key":"e_1_3_6_102_2","first-page":"395","article-title":"FIREFISH Parts 1 and 2: 24-month safety and efficacy of risdiplam in type 1 SMA","volume":"28","author":"Masson R","year":"2021","unstructured":"Masson R, Boespflug-Tanguy O, Darras BT, et al. FIREFISH Parts 1 and 2: 24-month safety and efficacy of risdiplam in type 1 SMA. Eur J Neurol 2021; 28: 395\u2013396.","journal-title":"Eur J Neurol"},{"key":"e_1_3_6_103_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.1302"},{"key":"e_1_3_6_104_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102047"},{"key":"e_1_3_6_105_2","unstructured":"Servais L Baranello G Boespflug-Tanguy O et al. FIREFISH parts 1 and 2: safety and efficacy of risdiplam in type 1 spinal muscular atrophy (3-year data). Presented at: European Paediatric Neurology Society Congress April 28\u2013May 2 2022; Glasgow UK."},{"key":"e_1_3_6_106_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27804"},{"key":"e_1_3_6_107_2","first-page":"72","article-title":"Real world treatment with risdiplam in adults with type-2 spinal muscular atrophy at St George\u2019s Hospital, London","volume":"93","author":"Ambawatte SB","year":"2022","unstructured":"Ambawatte SB, Weidner D, Chatfield S, et al. Real world treatment with risdiplam in adults with type-2 spinal muscular atrophy at St George\u2019s Hospital, London. J Neurol Neurosurg Psychiatry 2022; 93: 72.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_6_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2021.12.006"},{"key":"e_1_3_6_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2023.04.007"},{"key":"e_1_3_6_110_2","article-title":"Risdiplam in children with spinal muscular atrophy: real-world experience after one year of treatment","volume":"9","author":"Gomez Garcia de la Banda M","year":"2022","unstructured":"Gomez Garcia de la Banda M, Bouadi A, Spigarelli M, et al. Risdiplam in children with spinal muscular atrophy: real-world experience after one year of treatment. J Neuromuscul Dis 2022; 9: S191\u2013S192.","journal-title":"J Neuromuscul Dis"},{"key":"e_1_3_6_111_2","article-title":"Real-world experience after one year treating SMA children with risdiplam","volume":"32","author":"Gomez Garcia de la Banda M","year":"2022","unstructured":"Gomez Garcia de la Banda M, Garcia-Uzquiano R, Benesit A, et al. Real-world experience after one year treating SMA children with risdiplam. Neuromuscul Disord 2022; 32: S62.","journal-title":"Neuromuscul Disord"},{"key":"e_1_3_6_112_2","first-page":"310","article-title":"Preliminary real-world treatment patterns and outcomes in patients with spinal muscular atrophy (SMA) collected from the RESTORE registry","volume":"15","author":"Servais L","year":"2020","unstructured":"Servais L, Day JW, De Vivo DC, et al. Preliminary real-world treatment patterns and outcomes in patients with spinal muscular atrophy (SMA) collected from the RESTORE registry. Orphanet J Rare Dis 2020; 15: 310.","journal-title":"Orphanet J Rare Dis"},{"key":"e_1_3_6_113_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.96.15_supplement.2346"},{"key":"e_1_3_6_114_2","first-page":"117","article-title":"Switching therapies: safety profile of onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with risdiplam","volume":"41","author":"Tosi M","year":"2022","unstructured":"Tosi M, Catteruccia M, Cherchi C, et al. Switching therapies: safety profile of onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with risdiplam. Acta Myol 2022; 41: 117\u2013120.","journal-title":"Acta Myol"},{"key":"e_1_3_6_115_2","article-title":"Feeding and swallowing problems in SMA: a pilot observational study testing the usefulness of the IOPI pressure measurement system","volume":"31","author":"Ben Mechri S","year":"2021","unstructured":"Ben Mechri S, Deconinck N. Feeding and swallowing problems in SMA: a pilot observational study testing the usefulness of the IOPI pressure measurement system. Neuromuscul Disord 2021; 31: S125\u2013S126.","journal-title":"Neuromuscul Disord"},{"key":"e_1_3_6_116_2","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2024.2320880"},{"key":"e_1_3_6_117_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-240007"},{"key":"e_1_3_6_118_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-019-00874-6"},{"key":"e_1_3_6_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2009.11.014"},{"key":"e_1_3_6_120_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25705"},{"key":"e_1_3_6_121_2","doi-asserted-by":"publisher","DOI":"10.1097\/PHM.0000000000001869"},{"key":"e_1_3_6_122_2","doi-asserted-by":"publisher","DOI":"10.1589\/jpts.27.3631"},{"key":"e_1_3_6_123_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092319"},{"key":"e_1_3_6_124_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200614"},{"key":"e_1_3_6_125_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-221667"},{"key":"e_1_3_6_126_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2004.11.049"},{"key":"e_1_3_6_127_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00156"},{"key":"e_1_3_6_128_2","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14766"},{"key":"e_1_3_6_129_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00455-014-9541-x"},{"key":"e_1_3_6_130_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70137-5"},{"key":"e_1_3_6_131_2","doi-asserted-by":"publisher","DOI":"10.1111\/1460-6984.12332"},{"key":"e_1_3_6_132_2","doi-asserted-by":"publisher","DOI":"10.1111\/1460-6984.12613"},{"key":"e_1_3_6_133_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2019.109818"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/22143602241303373","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/22143602241303373","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/22143602241303373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:50:07Z","timestamp":1777506607000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/22143602241303373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":132,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1177\/22143602241303373"],"URL":"https:\/\/doi.org\/10.1177\/22143602241303373","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]}}}